Scholarlink

Aim <p>Previous findings have demonstrated that intravitreal sustained-release dexamethasone (DEX) implants improve functional and anatomical outcomes in patients with cystoid macular edema (CME) following cataract surgery; however, data on the influence of different surgical indications remain limited. This study aims to evaluate the efficacy of DEX implants in patients with persistent postoperative CME following vitrectomy, and to assess differences in treatment response regarding surgical indication, phakic status, and prior treatment received before DEX.</p> Methods <p>In this single-center study, we retrospectively reviewed data from 57&#xa0;patients (57&#xa0;eyes) who received a DEX implant for persistent postoperative CME following vitrectomy; main outcome measures were change in best corrected visual acuity (BCVA) and central retinal thickness (CRT). We then measured the effect of treatment outcomes across subgroups of patients according to surgical indication (rhegmatogenous retinal detachment vs. epiretinal membrane), phakic status, and prior receipt of subtenon triamcinolone.</p> Results <p>Patient eyes receiving a DEX implant achieved a significant improvement in both functional and anatomical outcomes: BCVA gain, 0.53&#xa0;to&#xa0;0.47 logMAR (<i>p</i> = 0.0180); CRT reduction, 453.5&#xa0;µm&#xa0;to&#xa0;381.6&#xa0;µm (<i>p</i> &lt; 0.0001). The mean number of DEX implants received was&#xa0;1.74, with no significant differences observed between patient subgroups. Subgroup comparisons did not show any significant impacts on BCVA or CRT by either surgical indication or type of surgery.</p> Conclusion <p>Sustained-release DEX implants provided immediate and lasting functional and anatomical benefits in patients with persistent postoperative CME. Outcomes such as the required number of DEX implants or treatment response were not significantly impacted by subgroup factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intravitreal sustained-release dexamethasone implant for the treatment of postoperative cystoid macular edema following vitrectomy

  • 期刊论文

  • 发表日期：

    2026年3月26日

查看全文
  • Elisa Huynh,
  • Argyrios Chronopoulos,
  • Lucrezia Langbein,
  • Lars-Olof Hattenbach

摘要

Aim

Previous findings have demonstrated that intravitreal sustained-release dexamethasone (DEX) implants improve functional and anatomical outcomes in patients with cystoid macular edema (CME) following cataract surgery; however, data on the influence of different surgical indications remain limited. This study aims to evaluate the efficacy of DEX implants in patients with persistent postoperative CME following vitrectomy, and to assess differences in treatment response regarding surgical indication, phakic status, and prior treatment received before DEX.

Methods

In this single-center study, we retrospectively reviewed data from 57 patients (57 eyes) who received a DEX implant for persistent postoperative CME following vitrectomy; main outcome measures were change in best corrected visual acuity (BCVA) and central retinal thickness (CRT). We then measured the effect of treatment outcomes across subgroups of patients according to surgical indication (rhegmatogenous retinal detachment vs. epiretinal membrane), phakic status, and prior receipt of subtenon triamcinolone.

Results

Patient eyes receiving a DEX implant achieved a significant improvement in both functional and anatomical outcomes: BCVA gain, 0.53 to 0.47 logMAR (p = 0.0180); CRT reduction, 453.5 µm to 381.6 µm (p < 0.0001). The mean number of DEX implants received was 1.74, with no significant differences observed between patient subgroups. Subgroup comparisons did not show any significant impacts on BCVA or CRT by either surgical indication or type of surgery.

Conclusion

Sustained-release DEX implants provided immediate and lasting functional and anatomical benefits in patients with persistent postoperative CME. Outcomes such as the required number of DEX implants or treatment response were not significantly impacted by subgroup factors.